Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Akt Inhibitor GSK2141795|OTHER: Laboratory Biomarker Analysis|DRUG: Trametinib
Sponsor: National Cancer Institute (NCI)
Collaborators: GlaxoSmithKline